242 related articles for article (PubMed ID: 38145833)
21. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
[TBL] [Abstract][Full Text] [Related]
22. Hepatic proteome analysis reveals altered mitochondrial metabolism and suppressed acyl-CoA synthetase-1 in colon-26 tumor-induced cachexia.
Khamoui AV; Tokmina-Roszyk D; Rossiter HB; Fields GB; Visavadiya NP
Physiol Genomics; 2020 May; 52(5):203-216. PubMed ID: 32146873
[TBL] [Abstract][Full Text] [Related]
23. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
[TBL] [Abstract][Full Text] [Related]
24. New drugs for the anorexia-cachexia syndrome.
Davis MP
Curr Oncol Rep; 2002 May; 4(3):264-74. PubMed ID: 11937018
[TBL] [Abstract][Full Text] [Related]
25. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.
Abe K; Shibata K; Naito T; Otsuka A; Karayama M; Maekawa M; Miyake H; Suda T; Kawakami J
Eur J Clin Pharmacol; 2022 Jan; 78(1):77-87. PubMed ID: 34410448
[TBL] [Abstract][Full Text] [Related]
26. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.
Sato K; Onuma E; Yocum RC; Ogata E
Semin Oncol; 2003 Oct; 30(5 Suppl 16):167-73. PubMed ID: 14613038
[TBL] [Abstract][Full Text] [Related]
27. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
28. Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes.
Goggi JL; Tan YX; Hartimath SV; Jieu B; Hwang YY; Jiang L; Boominathan R; Cheng P; Yuen TY; Chin HX; Tang JR; Larbi A; Chacko AM; Renia L; Johannes C; Robins EG
Mol Imaging Biol; 2020 Oct; 22(5):1392-1402. PubMed ID: 32705455
[TBL] [Abstract][Full Text] [Related]
29. Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?
Coss CC; Clinton SK; Phelps MA
Clin Cancer Res; 2018 Dec; 24(23):5787-5789. PubMed ID: 30018117
[TBL] [Abstract][Full Text] [Related]
30. The effect of the neonatal Fc receptor on human IgG biodistribution in mice.
Chen N; Wang W; Fauty S; Fang Y; Hamuro L; Hussain A; Prueksaritanont T
MAbs; 2014; 6(2):502-8. PubMed ID: 24492305
[TBL] [Abstract][Full Text] [Related]
31. EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice.
Kerr HL; Krumm K; Lee II; Anderson B; Christiani A; Strait L; Breckheimer BA; Irwin B; Jiang AS; Rybachok A; Chen A; Caeiro L; Dacek E; Hall DB; Kostyla CH; Hales LM; Soliman TM; Garcia JM
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1337-1348. PubMed ID: 36942661
[TBL] [Abstract][Full Text] [Related]
32. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
33. Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation.
Ohira T; Nishio K; Ohe Y; Arioka H; Nishio M; Funayama Y; Ogasawara H; Fukuda M; Yazawa K; Kato H; Saijo N
J Cancer Res Clin Oncol; 1996; 122(12):711-5. PubMed ID: 8954167
[TBL] [Abstract][Full Text] [Related]
34. Role of NF-kappaB and cytokine in experimental cancer cachexia.
Zhou W; Jiang ZW; Tian J; Jiang J; Li N; Li JS
World J Gastroenterol; 2003 Jul; 9(7):1567-70. PubMed ID: 12854165
[TBL] [Abstract][Full Text] [Related]
35. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.
Israel EJ; Wilsker DF; Hayes KC; Schoenfeld D; Simister NE
Immunology; 1996 Dec; 89(4):573-8. PubMed ID: 9014824
[TBL] [Abstract][Full Text] [Related]
36. Paeoniflorin alleviated muscle atrophy in cancer cachexia through inhibiting TLR4/NF-κB signaling and activating AKT/mTOR signaling.
Zhu Z; Li C; Gu X; Wang X; Zhang G; Fan M; Zhao Y; Liu X; Zhang X
Toxicol Appl Pharmacol; 2024 Mar; 484():116846. PubMed ID: 38331105
[TBL] [Abstract][Full Text] [Related]
37. Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium.
Cejas RB; Ferguson DC; Quiñones-Lombraña A; Bard JE; Blanco JG
Sci Rep; 2019 Jun; 9(1):8674. PubMed ID: 31209240
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
Tseng YC; Kulp SK; Lai IL; Hsu EC; He WA; Frankhouser DE; Yan PS; Mo X; Bloomston M; Lesinski GB; Marcucci G; Guttridge DC; Bekaii-Saab T; Chen CS
J Natl Cancer Inst; 2015 Dec; 107(12):djv274. PubMed ID: 26464423
[TBL] [Abstract][Full Text] [Related]
39. Macrophages protect against loss of adipose tissue during cancer cachexia.
Erdem M; Möckel D; Jumpertz S; John C; Fragoulis A; Rudolph I; Wulfmeier J; Springer J; Horn H; Koch M; Lurje G; Lammers T; Olde Damink S; van der Kroft G; Gremse F; Cramer T
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1128-1142. PubMed ID: 31318182
[TBL] [Abstract][Full Text] [Related]
40. MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.
Huot JR; Pin F; Essex AL; Bonetto A
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
